SARA FRAZIER: Open Payments
NPI 1427417039 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,198 in 157 payments from 29 companies in 2025. Trend: 2023 $987 · 2024 $2,224 · 2025 $3,198
Food & beverage: $3,198
| Company | Payments | Amount |
|---|---|---|
| ARGENX US, INC. | 13 | $376 |
| ABBVIE INC. | 28 | $372 |
| EMD Serono, Inc. | 14 | $310 |
| UCB, Inc. | 12 | $299 |
| Neurocrine BioSciences, Inc. | 13 | $227 |
| Novartis Pharmaceuticals Corporation | 11 | $207 |
| Lilly USA, LLC | 10 | $164 |
| SK Life Science, Inc. | 6 | $134 |
| Biogen, Inc. | 5 | $118 |
| Eisai Inc. | 5 | $116 |
Products named: VYVGART HYTRULO, QULIPTA, INGREZZA, KESIMPTA, KISUNLA, Rystiggo, TYSABRI, Leqembi.
Industry payments across UT — which companies pay providers there.
